GO:0070123 transforming growth factor beta receptor activity, type III: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070123 describes the molecular function of type III TGF-beta receptors (betaglycan and endoglin), which bind TGF-beta ligands and present them to type I and type II receptors to initiate signaling.
• Type III receptors are not signaling kinases; they act as co-receptors that facilitate ligand binding and enhance canonical TGF-beta/SMAD signaling.
• Loss of type III receptor expression is implicated in prostate cancer progression and other malignancies, where it can act as a tumor suppressor.
• TGF-beta signaling, including type III receptor function, is a key driver of fibrosis in organs such as lung and liver.
• The term is annotated to the molecular function ontology and is distinct from type I and type II receptor activities.
• Studying GO:0070123 requires tools that measure ligand-receptor interactions, downstream SMAD phosphorylation, and cellular responses like fibrosis or proliferation.
Description
Transforming growth factor beta (TGF-beta) signaling is a fundamental pathway that regulates cell proliferation, differentiation, migration, and extracellular matrix production. The type III TGF-beta receptor, also known as betaglycan or endoglin, is a co-receptor that lacks intrinsic kinase activity but is essential for efficient ligand presentation to the signaling type I and type II receptors. The Gene Ontology term GO:0070123, transforming growth factor beta receptor activity, type III, captures this molecular function. Understanding this activity is critical because dysregulation of TGF-beta signaling contributes to cancer, fibrosis, and developmental disorders. Researchers studying this term need reliable models to dissect the contribution of type III receptors to ligand binding and downstream signaling. This article provides a comprehensive overview of GO:0070123, including its definition, mechanism, key genes, disease relevance, and experimental approaches.
transforming growth factor beta receptor activity, type III At A Glance
| GO ID | GO:0070123 |
|---|---|
| GO term | transforming growth factor beta receptor activity, type III |
| Ontology | molecular_function |
| Synonym | betaglycan, endoglin, transforming growth factor beta ligand binding to type III receptor, type III TGF-beta receptor activity, type III TGFbeta receptor activity, type III transforming growth factor beta receptor activity |
| Major function | Binds TGF-beta ligands and facilitates their presentation to type I and type II receptors, thereby initiating or modulating TGF-beta signaling. |
| Cellular location | Cell surface membrane (as a co-receptor). |
| Representative genes | TGFBR3 (betaglycan), ENG (endoglin). |
| Related pathways | TGF-beta/SMAD signaling, fibrosis, cancer progression. |
What Is GO:0070123?
GO:0070123, transforming growth factor beta receptor activity, type III, is a molecular function defined as combining with transforming growth factor beta to initiate a change in cell activity, while facilitating ligand binding to type I and type II TGF-beta receptors. In other words, it is the activity of a cell surface co-receptor that binds TGF-beta ligands and presents them to the signaling receptors, thereby enhancing or modulating the cellular response to TGF-beta.
Why Is transforming growth factor beta receptor activity, type III Important in Cell Biology?
GO:0070123 is important because type III TGF-beta receptors are critical modulators of TGF-beta signaling, which controls a wide range of biological processes including cell growth, differentiation, apoptosis, and extracellular matrix remodeling. Dysregulation of this activity is linked to cancer, fibrosis, and other diseases, making it a potential therapeutic target.
• Type III receptors enhance TGF-beta binding to type II receptors, amplifying downstream SMAD signaling.
• Loss of type III receptor expression is associated with prostate cancer progression and poor prognosis.
• TGF-beta signaling via type III receptors contributes to fibrosis in lung and liver.
• The term is essential for understanding how cells fine-tune responses to TGF-beta ligands.
• Type III receptors can also bind other ligands such as inhibin and BMPs, but GO:0070123 specifically refers to TGF-beta binding.
• Studying this activity helps identify therapeutic strategies for cancer and fibrotic diseases.
• It provides a molecular handle for CRISPR-based functional studies of TGFBR3 and ENG.
• Understanding GO:0070123 aids in interpreting transcriptomic and proteomic data in TGF-beta-related research.
What Happens During transforming growth factor beta receptor activity, type III?
Ligand Binding and Presentation
In simple terms: The type III receptor grabs TGF-beta and holds it ready for the signaling receptors.
Type III TGF-beta receptors, such as betaglycan and endoglin, bind TGF-beta ligands with high affinity. This binding does not directly activate signaling but instead presents the ligand to type II receptors, facilitating the formation of a functional ligand-receptor complex.
Facilitation of Type I and Type II Receptor Activation
In simple terms: The type III receptor helps the type I and type II receptors come together and turn on.
By concentrating TGF-beta at the cell surface and promoting its interaction with type II receptors, type III receptors enhance the phosphorylation of type I receptors by type II receptors. This leads to activation of the canonical SMAD2/3 pathway.
Modulation of Signaling Strength and Specificity
In simple terms: The type III receptor can dial up or down the TGF-beta signal.
Depending on cellular context, type III receptors can either enhance or inhibit TGF-beta signaling. For example, soluble forms of betaglycan can sequester TGF-beta and reduce signaling, while membrane-bound forms potentiate it.
Integration with Other Pathways
In simple terms: The type III receptor also connects TGF-beta signaling to other cellular pathways.
Type III receptors can interact with other signaling molecules and modulate pathways such as BMP signaling. This crosstalk is important for fine-tuning cellular responses.
Key Genes Involved in GO:0070123 transforming growth factor beta receptor activity, type III
The following genes encode proteins that exhibit or regulate type III TGF-beta receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFBR3 | Encodes betaglycan, a type III TGF-beta receptor that binds TGF-beta and presents it to type II receptors. | Frequently lost in prostate cancer; potential tumor suppressor. |
| ENG | Encodes endoglin, a type III TGF-beta receptor highly expressed in endothelial cells. | Mutations cause hereditary hemorrhagic telangiectasia; role in angiogenesis. |
| TGFB1 | Ligand that binds to type III receptors and initiates signaling. | Key driver of fibrosis and cancer. |
| TGFBR2 | Type II receptor that is facilitated by type III receptors. | Mutations in TGFBR2 cause Marfan syndrome and cancers. |
| TGFBR1 | Type I receptor activated downstream of type II receptor. | Target for cancer therapy. |
| SMAD2 | Downstream effector phosphorylated upon TGF-beta signaling. | Readout of pathway activity. |
| SMAD3 | Downstream effector phosphorylated upon TGF-beta signaling. | Readout of pathway activity. |
| SMAD4 | Common mediator of TGF-beta superfamily signaling. | Tumor suppressor in pancreatic cancer. |
| GDF15 | Member of TGF-beta superfamily that can modulate TGF-beta signaling. | Involved in liver fibrosis and metabolism. |
| ATF3 | Transcription factor that can regulate TGF-beta signaling and fibrosis. | Implicated in pulmonary fibrosis. |
| LINC00941 | Long non-coding RNA that regulates fibroblast-to-myofibroblast differentiation. | Potential target in fibrosis. |
| ELAVL1 | RNA-binding protein that stabilizes mRNAs and modulates fibrosis. | Regulates autophagy and TGF-beta crosstalk. |
| FOXP3 | Transcription factor in regulatory T cells and macrophages. | Modulates inflammation and TGF-beta signaling. |
| BECN1 | Autophagy-related gene that crosstalks with TGF-beta signaling. | Implicated in endometriosis and cancer. |
| MAP1LC3B | Autophagy marker that can be regulated by TGF-beta. | Used to monitor autophagy. |
| EPAS1 | Hypoxia-inducible factor that can interact with TGF-beta pathways. | Relevant in myelodysplastic syndromes. |
| HBB | Hemoglobin beta chain; TGF-beta signaling affects erythropoiesis. | Mutations cause beta-thalassemia. |
| ACVR2B | Activin receptor that can be modulated by TGF-beta superfamily ligands. | Target of luspatercept in MDS. |
How Is transforming growth factor beta receptor activity, type III Regulated?
Type III TGF-beta receptor activity is regulated at multiple levels. Expression of TGFBR3 and ENG is controlled by transcription factors and epigenetic mechanisms. Soluble forms of betaglycan can be generated by proteolytic cleavage, acting as decoys to sequester TGF-beta and reduce signaling. Additionally, endoglin expression is modulated by hypoxia and inflammatory cytokines. Crosstalk with other pathways, such as autophagy, can influence receptor turnover and signaling output.
transforming growth factor beta receptor activity, type III and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR3 | Prostate cancer progression; tumor suppressor | Knockout in prostate cancer cell lines; overexpression in normal prostate cells |
| ENG | Hereditary hemorrhagic telangiectasia; angiogenesis | Knockout in endothelial cells; knock-in of patient mutations |
| TGFB1 | Fibrosis; cancer | Overexpression in fibroblasts; KO in mouse models |
| SMAD3 | Fibrosis; cancer | Point mutation to block phosphorylation; KO in hepatic stellate cells |
| GDF15 | Liver fibrosis; metabolic regulation | Overexpression in hepatocytes; KO in mouse liver |
Cancer
Loss of type III TGF-beta receptor expression, particularly betaglycan (TGFBR3), is frequently observed in prostate cancer and correlates with disease progression. Betaglycan acts as a tumor suppressor by inhibiting cell proliferation and migration, and its loss enhances TGF-beta signaling that promotes tumor growth.
Fibrosis
TGF-beta signaling is a central driver of fibrosis in organs such as lung and liver. Type III receptors modulate this process; for example, GDF15 attenuates TGF-beta1/SMAD3 signaling and inhibits liver fibrosis. In pulmonary fibrosis, LINC00941 and ATF3 regulate fibroblast-to-myofibroblast differentiation through autophagy-dependent mechanisms that intersect with TGF-beta signaling.
Hereditary Hemorrhagic Telangiectasia
Mutations in ENG, which encodes endoglin, cause hereditary hemorrhagic telangiectasia type 1, a vascular disorder. Endoglin is a type III TGF-beta receptor that is critical for endothelial cell function and angiogenesis.
From transforming growth factor beta receptor activity, type III-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TGFBR3 enhance TGF-beta signaling in prostate cancer? | TGFBR3 knockout in prostate cancer cell lines (e.g., PC-3) followed by SMAD phosphorylation assay |
| How does endoglin mutation affect angiogenesis? | ENG knockout or point mutation in endothelial cells (HUVECs) and tube formation assay |
| Can overexpression of betaglycan inhibit fibrosis? | TGFBR3 overexpression in hepatic stellate cells or fibroblasts, measure collagen production |
| What is the role of type III receptor in TGF-beta ligand presentation? | Knock-in of tagged TGFBR3 (e.g., HA-tag) for co-immunoprecipitation with TGF-beta |
| Does GDF15 modulate TGF-beta signaling via type III receptors? | GDF15 overexpression or knockout in hepatocytes, measure SMAD3 phosphorylation |
| How does autophagy crosstalk with type III receptor activity? | Knockout of BECN1 or ATG5 in cells expressing type III receptors, measure TGF-beta signaling |
How to Study the transforming growth factor beta receptor activity, type III Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ligand binding assay | Direct binding of TGF-beta to type III receptors | Determine affinity and specificity of betaglycan/endoglin |
| Phospho-SMAD Western blot | Activation of canonical TGF-beta signaling | Assess functional impact of type III receptor manipulation |
| Co-immunoprecipitation | Protein-protein interactions | Map interactions between type III and type II receptors |
| CRISPR knockout screen | Genes required for TGF-beta signaling | Identify novel regulators of fibrosis or cancer |
| RNA-seq | Transcriptional changes upon pathway modulation | Global gene expression profiling in response to TGF-beta |
| Immunofluorescence | Subcellular localization of receptors | Visualize type III receptor trafficking |
| Autophagy flux assay | Autophagic activity | Study crosstalk between autophagy and TGF-beta |
| ELISA | Soluble ligand or receptor levels | Measure soluble betaglycan in serum |
Ligand Binding Assays
Radiolabeled or fluorescently labeled TGF-beta can be used to measure binding to type III receptors on cell surfaces. Competition assays with unlabeled ligand or soluble receptors can determine affinity and specificity.
SMAD Phosphorylation Western Blot
Activation of TGF-beta signaling downstream of type III receptors is commonly assessed by Western blot for phosphorylated SMAD2/3. This method quantifies pathway activity in response to ligands or receptor manipulation.
Co-Immunoprecipitation
To study interactions between type III receptors and type II receptors or ligands, co-immunoprecipitation can be performed using tagged or endogenous proteins. This reveals complex formation and facilitates mapping of binding domains.
CRISPR Screens
Genome-wide CRISPR knockout screens can identify genes that modulate TGF-beta signaling, including modifiers of type III receptor activity. Such screens have been used to uncover regulators of fibrosis and cancer pathways.
How CRISPR Can Be Used to Study GO:0070123 transforming growth factor beta receptor activity, type III
Knockout
CRISPR knockout of TGFBR3 or ENG can abolish type III receptor activity, leading to reduced TGF-beta signaling. This is useful to study the contribution of these receptors to cancer, fibrosis, and angiogenesis.
Point Mutation
Introducing point mutations in the ligand-binding domain of TGFBR3 or ENG can dissect the specific residues required for TGF-beta binding and presentation. Such models help distinguish between ligand-dependent and independent functions.
Knock-in
Knock-in of tagged versions of TGFBR3 or ENG (e.g., HA, GFP) allows for live-cell imaging and proteomic analysis of receptor complexes. This approach can reveal dynamic interactions with type I and type II receptors.
Overexpression
Overexpression of TGFBR3 or ENG can enhance TGF-beta signaling and is used to study the effects of increased type III receptor activity on cell proliferation, migration, and fibrosis.
How EDITGENE Supports transforming growth factor beta receptor activity, type III Research
Researchers studying transforming growth factor beta receptor activity, type III-related genes often need to determine whether a candidate gene is causally involved in ligand binding, signaling modulation, or disease progression. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for transforming growth factor beta receptor activity, type III research.
Frequently Asked Questions About transforming growth factor beta receptor activity, type III
What is GO:0070123?
GO:0070123 is a Gene Ontology molecular function term that describes transforming growth factor beta receptor activity, type III. It refers to the ability of type III TGF-beta receptors (like betaglycan and endoglin) to bind TGF-beta and facilitate its presentation to type I and type II receptors.
What genes are involved in transforming growth factor beta receptor activity, type III?
The main genes are TGFBR3 (betaglycan) and ENG (endoglin). Other genes such as TGFB1, TGFBR2, and SMADs are part of the downstream signaling pathway.
What is the function of type III TGF-beta receptor?
Type III receptors bind TGF-beta ligands and present them to type II receptors, enhancing the formation of active ligand-receptor complexes and downstream SMAD signaling.
How is type III TGF-beta receptor activity studied?
Common methods include ligand binding assays, phospho-SMAD Western blot, co-immunoprecipitation, and CRISPR knockout models.
What diseases are associated with type III TGF-beta receptor dysfunction?
Dysfunction is linked to prostate cancer progression, hereditary hemorrhagic telangiectasia, and fibrosis in lung and liver.
Can CRISPR be used to study GO:0070123?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the role of type III receptors in TGF-beta signaling.
What is betaglycan?
Betaglycan is a proteoglycan encoded by TGFBR3 that functions as a type III TGF-beta receptor, binding TGF-beta and facilitating signaling.
What is endoglin?
Endoglin is a type III TGF-beta receptor encoded by ENG, highly expressed in endothelial cells, and involved in angiogenesis and vascular homeostasis.
How does type III receptor modulate TGF-beta signaling?
It can enhance signaling by presenting ligand to type II receptors, or inhibit signaling when present as a soluble decoy.
What are the therapeutic implications of targeting type III TGF-beta receptors?
Modulating type III receptor activity could treat cancer and fibrosis; for example, restoring betaglycan expression may suppress tumor growth.
Conclusion
GO:0070123, transforming growth factor beta receptor activity, type III, is a critical molecular function that modulates TGF-beta signaling by facilitating ligand presentation to signaling receptors. Its dysregulation is implicated in cancer, fibrosis, and vascular disorders. Understanding this activity through CRISPR-based models and biochemical assays can reveal new therapeutic opportunities. EDITGENE provides the tools and expertise to accelerate such research.
References
- 1. Cai W et al.. 2023. FOXP3+ macrophage represses acute ischemic stroke-induced neural inflammation.. Autophagy 19(4):1144-1163 PMID: 36170234
- 2. Devis-Jauregui L et al.. 2021. Autophagy in the physiological endometrium and cancer.. Autophagy 17(5):1077-1095 PMID: 32401642
- 3. Della Porta MG et al.. 2024. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.. Lancet Haematol 11(9):e646-e658 PMID: 39038479
- 4. Cappellini MD et al.. 2020. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.. N Engl J Med 382(13):1219-1231 PMID: 32212518
- 5. Zhang J et al.. 2022. ATF3 -activated accelerating effect of LINC00941/lncIAPF on fibroblast-to-myofibroblast differentiation by blocking autophagy depending on ELAVL1/HuR in pulmonary fibrosis.. Autophagy 18(11):2636-2655 PMID: 35427207
- 6. Jurado-Aguilar J et al.. 2024. GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway.. Metabolism 152:155772 PMID: 38176644
- 7. Platzbecker U et al.. 2023. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.. Lancet 402(10399):373-385 PMID: 37311468
- 8. Ajiboye S et al.. 2010. More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.. BJU Int 105(7):913-6 PMID: 20067462
